Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sylvain Simon

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Oncoimmunology|January 4, 2018
PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?Sylvain Simon, Nathalie Labarriere
Blood Cancer Discovery|October 18, 2021
Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple MyelomaSylvain Simon, Stanley R Riddell
Cancer Cell|April 12, 2022
Synthetic HLA-independent T cell receptors for cancer immunotherapySylvain Simon, Grace Bugos, Stanley R Riddell
Immunotherapy|January 18, 2018
Immunotherapies in transplantation and cancer: 22nd NAT meeting/2nd NAT LabEx IGO joint meeting; 1-2 June 2017, Nantes, FranceSylvain Simon, Maud Charpentier, Ignacio Anegon, et al.
Current Opinion in Immunology|September 27, 2021
Synthetic receptors for logic gated T cell recognition and functionSylvain Simon, Grace Bugos, Alex I Salter, et al.
Oncoimmunology|March 5, 2016
PD-1 expression conditions T cell avidity within an antigen-specific repertoireSylvain Simon, Virginie Vignard, Laetitia Florenceau, et al.
Frontiers in Immunology|September 15, 2018
TCR Analyses of Two Vast and Shared Melanoma Antigen-Specific T Cell Repertoires: Common and Specific FeaturesSylvain Simon, Zhong Wu, J Cruard, et al.
Cancer Research|December 8, 2017
Emergence of High-Avidity Melan-A-Specific Clonotypes as a Reflection of Anti-PD-1 Clinical EfficacySylvain Simon, Virginie Vignard, Emilie Varey, et al.
Cancer Immunology, Immunotherapy : CII|June 13, 2021
Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patientsBrigitte Dréno, Amir Khammari, Agnès Fortun, et al.
Oncoimmunology|July 10, 2024
Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytesGwenann Cadiou, Tiffany Beauvais, Lucine Marotte, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Oncoimmunology|January 4, 2018
PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?Sylvain Simon, Nathalie Labarriere
Blood Cancer Discovery|October 18, 2021
Dual Targeting with CAR T Cells to Limit Antigen Escape in Multiple MyelomaSylvain Simon, Stanley R Riddell
Cancer Cell|April 12, 2022
Synthetic HLA-independent T cell receptors for cancer immunotherapySylvain Simon, Grace Bugos, Stanley R Riddell
Immunotherapy|January 18, 2018
Immunotherapies in transplantation and cancer: 22nd NAT meeting/2nd NAT LabEx IGO joint meeting; 1-2 June 2017, Nantes, FranceSylvain Simon, Maud Charpentier, Ignacio Anegon, et al.
Current Opinion in Immunology|September 27, 2021
Synthetic receptors for logic gated T cell recognition and functionSylvain Simon, Grace Bugos, Alex I Salter, et al.
Oncoimmunology|March 5, 2016
PD-1 expression conditions T cell avidity within an antigen-specific repertoireSylvain Simon, Virginie Vignard, Laetitia Florenceau, et al.
Frontiers in Immunology|September 15, 2018
TCR Analyses of Two Vast and Shared Melanoma Antigen-Specific T Cell Repertoires: Common and Specific FeaturesSylvain Simon, Zhong Wu, J Cruard, et al.
Cancer Research|December 8, 2017
Emergence of High-Avidity Melan-A-Specific Clonotypes as a Reflection of Anti-PD-1 Clinical EfficacySylvain Simon, Virginie Vignard, Emilie Varey, et al.
Cancer Immunology, Immunotherapy : CII|June 13, 2021
Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patientsBrigitte Dréno, Amir Khammari, Agnès Fortun, et al.
Oncoimmunology|July 10, 2024
Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytesGwenann Cadiou, Tiffany Beauvais, Lucine Marotte, et al.
Pageof 3